Raymond James Financial Services Advisors Inc. increased its holdings in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) by 51.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 16,495 shares of the biopharmaceutical company’s stock after buying an additional 5,628 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in Keryx Biopharmaceuticals were worth $119,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. UBS Asset Management Americas Inc. lifted its stake in Keryx Biopharmaceuticals by 0.3% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 38,316 shares of the biopharmaceutical company’s stock worth $277,000 after purchasing an additional 102 shares in the last quarter. Legal & General Group Plc lifted its stake in Keryx Biopharmaceuticals by 1.2% in the 1st quarter. Legal & General Group Plc now owns 25,985 shares of the biopharmaceutical company’s stock worth $161,000 after purchasing an additional 300 shares in the last quarter. Rhumbline Advisers lifted its stake in Keryx Biopharmaceuticals by 0.3% in the 2nd quarter. Rhumbline Advisers now owns 99,711 shares of the biopharmaceutical company’s stock worth $721,000 after purchasing an additional 335 shares in the last quarter. Principal Financial Group Inc. lifted its stake in Keryx Biopharmaceuticals by 4.2% in the 2nd quarter. Principal Financial Group Inc. now owns 14,759 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 590 shares in the last quarter. Finally, Bank of America Corp DE lifted its stake in Keryx Biopharmaceuticals by 1.0% in the 1st quarter. Bank of America Corp DE now owns 108,558 shares of the biopharmaceutical company’s stock worth $669,000 after purchasing an additional 1,058 shares in the last quarter. 65.44% of the stock is owned by institutional investors.

Shares of Keryx Biopharmaceuticals, Inc. (NASDAQ KERX) opened at $5.03 on Thursday. The company has a current ratio of 4.46, a quick ratio of 3.76 and a debt-to-equity ratio of 13.95. Keryx Biopharmaceuticals, Inc. has a 52-week low of $4.47 and a 52-week high of $8.38.

Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.03). The company had revenue of $15.00 million for the quarter, compared to analysts’ expectations of $18.88 million. Keryx Biopharmaceuticals had a negative net margin of 323.92% and a negative return on equity of 10,954.62%. The business’s quarterly revenue was up 138.1% compared to the same quarter last year. During the same quarter last year, the business posted ($0.39) EPS. equities analysts forecast that Keryx Biopharmaceuticals, Inc. will post -1.36 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This story was originally published by Daily Political and is the property of of Daily Political. If you are viewing this story on another domain, it was illegally stolen and republished in violation of US and international copyright and trademark legislation. The original version of this story can be read at https://www.dailypolitical.com/2017/11/16/raymond-james-financial-services-advisors-inc-has-119000-position-in-keryx-biopharmaceuticals-inc-kerx.html.

KERX has been the topic of several recent analyst reports. Zacks Investment Research upgraded shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, October 16th. Maxim Group reiterated a “buy” rating and issued a $9.00 target price on shares of Keryx Biopharmaceuticals in a research note on Thursday, July 20th. Morgan Stanley reiterated an “equal weight” rating and issued a $7.00 target price (up from $4.00) on shares of Keryx Biopharmaceuticals in a research note on Tuesday, July 25th. Cowen and Company reiterated a “market perform” rating on shares of Keryx Biopharmaceuticals in a research note on Tuesday, July 25th. Finally, ValuEngine cut shares of Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, September 21st. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $7.35.

Keryx Biopharmaceuticals Company Profile

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Institutional Ownership by Quarter for Keryx Biopharmaceuticals (NASDAQ:KERX)

Receive News & Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.